The 2019 Worldwide Market for Targeted Cancer Therapeutics

Table of Contents

Chapter 1: Executive Summary

• Overview
• Scope and Methodology
• Market Overview and Analysis
  • Figure 1-1: Global Targeted Cancer Therapeutic Market Size and Forecast, 2010-2025 ($millions) (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, others)

Chapter 2: Introduction

• Global Cancer Burden
  • Figure 2-1: Global Cancer Incidence Trends, 2010-2040
  • Figure 2-2: Incidence of Cancer by Type, 2018 (Lung, Breast, Colorectal, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder)
  • Figure 2-3: Distribution of Cancer Incidence by Type, 2018 (Lung, Breast, Colorectal, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder, Others)
• Introduction to Cancer
• Biochemistry of Cancer Cells
• Causes of Cancer Growth May Shed Light on Treatment
• Environmental Factors, DNA, RNA
  • Table 2-1: Virus Association with Human Cancer
• Cellular Oncogenes
• Tumor Suppressor Genes
• Cancer Treatment Approaches
  • Table 2-2: Characteristics of Cancer Treatment Approaches (chemotherapy, hormone therapy, targeted therapy)
• What Is Targeted Cancer Therapy?
• Trends in Research and Development of Targeted Cancer Therapeutics
• Cancer Treatment Market Outlook: Targeted vs. Broad Treatments
  • Figure 2-4: Targeted vs. Broad Treatments for Cancer, 2010-2025
• Monoclonal Antibodies: The Leading Area of Cancer Targeted Therapy

Chapter 3: Targeted Cancer Therapies: Monoclonal Antibodies

• Monoclonal Antibody Overview
• Market Outlook
  • Figure 3-1: Cancer Monoclonal Antibody Market, 2018-2025  ($ millions)
• Principal Products
  • Table 3-1: Top 10 Cancer Indicated Monoclonal Antibodies, 2017 and 2018 Sales  (millions $)
  • Figure 3-2: Top 10 Cancer Indicated Monoclonal Antibodies, 2017 and 2018 Sales  (millions $)
• Avastin (bevacizumab)
• Darzalex (daratumumab)
• Erbitux (cetuximab)
• Herceptin (trastuzumab)
• Kadcyla (ado-trastuzumab emtansine)
• Keytruda (pembrolizumab)
• Opdivo (nivolumab)
• Perjeta (pertuzumab)
• Rituxan (rituximab)
• Yervoy (ipilimumab)
• Xgeva (denosumab)
  • Table 3-2: Monoclonal Antibodies in Cancer Therapy
• Market Breakdown of Monoclonal Antibodies
• Cancer Monoclonal Antibody Market by Target
  • Table 3-3: Cancer Monoclonal Antibody Market by Target, 2018 and Forecast 2025  ($ millions) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Figure 3-3: Cancer Monoclonal Antibody Market by Target, 2018 and 2025 ($ millions) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Figure 3-4: Cancer Monoclonal Antibody Market Distribution by Target, 2018 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Figure 3-5: Cancer Monoclonal Antibody Market Distribution by Target, 2025 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
• Cancer Monoclonal Antibody Market by Type
  • Figure 3-6: Development of the mAb Cancer Treatment Market, 2010-2025 (Breast Cancer, Colorectal Cancer, Lymphoma, Leukemia, Myeloma, Melanoma, Lung, Renal, Others)
  • Table 3-4: Cancer Treatment mAb Market by Type, 2018-2025 ($ millions) (Breast Cancer, Colorectal Cancer, Lymphoma, Leukemia, Myeloma, Melanoma, Lung Cancer, Renal Cell Carcinoma)
  • Figure 3-7: Monoclonal Antibody Market by Cancer Type, 2018 and 2025 ($ millions) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
  • Figure 3-8: Monoclonal Antibody Market, Distribution by Cancer Type, 2018 (%) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
  • Figure 3-9: Monoclonal Antibody Market Distribution by Indication, 2025 (%) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
• Regional Market Summary
  • Figure: 3-10: Cancer Monoclonal Antibody Market Summary by Geographic Region, 2018 and 2025  ($ millions) (United States, EMEA, Asia Pacific, Latin America)
• Competitor Summary
• Genentech/Roche
• Bristol-Myers Squibb
• Merck & Co.
• Amgen
• Janssen Biotech/J&J
• Eli Lilly & Co.
• EMD Serono
  • Table 3-5: Cancer Monoclonal Antibody Competitor Market Share – Top Seven, 2018 ($ millions)

Chapter 4: Targeted Cancer Therapies: Tyrosine Kinase Inhibitors

• Tyrosine Kinase Inhibitor Overview
• Market Outlook
  • Figure 4-1: Tyrosine Kinase Inhibitor Market, 2018-2025  ($ millions)
• Principal Products
  • Table 4-1: Top 10 Cancer Indicated Tyrosine Kinase Inhibitors, 2017 and 2018 Sales  (millions $)
  • Figure 4-2: Top 10 Cancer Indicated Tyrosine Kinase Inhibitors, 2017 and 2018 Sales  (millions $)
• Imbruvica (ibrutinib)
• Sprycel (dasatinib)
• Tasigna (nilotinib)
• Tagrisso (osimertinib)
• Gleevec (imatinib)
• Mekinist+Tafinlar (trametinib + dabrafenib)
• Sutent (sunitinib)
• Jakafi/Jakavi (ruxolitinib)
• Nexavar (sorafenib)
• Votrient (pazopanib)
  • Table 4-2: Tyrosine Kinase Inhibitors in Cancer Therapy
• Market Breakdown of Tyrosine Kinase Inhibitors
• Cancer Tyrosine Kinase Inhibitor Market by Target
  • Table 4-3: Cancer TKI Market by Target, 2018 and Forecast 2025  ($ millions) (Single Target: ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
  • Figure 4-3: Cancer TKI Market by Target, 2018 and 2025 ($ millions) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
  • Figure 4-4: TKI Market Distribution by Target, 2018 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
  • Figure 4-5: TKI Market Distribution by Target, 2025 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
• Cancer Tyrosine Kinase Inhibitor Market by Type
  • Figure 4-6: Development of the TKI Cancer Treatment Market, 2010-2025 (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • Table 4-4: Cancer Treatment TKI Market by Type, 2018-2025 ($ millions) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal)
  • Figure 4-7: TKI Market by Cancer Indication, 2018 and 2025 ($ millions) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • Figure 4-8: TKI Market Distribution by Cancer Indication, 2018 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • Figure 4-9: TKI Market Distribution by Cancer Indication, 2025 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
• Regional Market Summary
  • Figure: 4-10: Cancer Tyrosine Kinase Inhibitor Market Summary by Geographic Region, 2018 and 2025  ($ millions) (United States, EMEA, Asia Pacific, Latin America)
• Competitor Summary
• Novartis
• AbbVie
• Johnson & Johnson
• AstraZeneca
• Pfizer
• Bristol-Myers Squibb
• Roche/Genentech
  • Table 4-5: Cancer TKI Competitor Market Share, 2018 ($ millions)

Chapter 5: Targeted Cancer Therapies: Angiogenesis Inhibitors

• Angiogenesis Inhibitor Overview
• Market Outlook
  • Figure 5-1: Angiogenesis Inhibitor Market, 2018-2025  ($ millions)
• Principal Products
• Pomalyst/Imnovid (pomalidomide)
• Revlimid (lenalidomide)
• Thalomid (thalidomide)
• Zaltrap (ziv-aflibercept)
  • Table 5-1: Angiogenesis Inhibitors in Cancer Therapy
• Regional Market Summary
  • Figure: 5-2: Cancer Angiogenesis Inhibitor Market Summary by Geographic Region, Estimated 2018 and 2025  ($ millions) (United States, EMEA, Asia Pacific, Latin America)
• Competitor Summary

Chapter 6: Targeted Cancer Therapies: CDK Inhibitors

• CDK Inhibitor Overview
• Market Outlook
  • Figure 6-1: CDK Inhibitor Market, 2018-2025:  ($ millions)
• Principal Products
• Ibrance (palbociclib)
• Kisqali (ribociclib)
  • Table 6-1: CDK Inhibitors in Cancer Therapy
• Regional Market Summary
  • Figure: 6-2: Cancer CDK Inhibitor Market Summary by Geographic Region, Estimated 2018 and 2025  ($ millions) (United States, EMEA, Asia Pacific, Latin America)
• Competitor Summary
• Pfizer
• Novartis
  • Table 6-2: Cancer CDK Inhibitors Competitor Market Share, 2018 ($ millions)

Chapter 7: Targeted Cancer Therapies: Proteasome Inhibitors

• Proteasome Inhibitor Overview
• Market Outlook
  • Figure 7-1: Proteasome Inhibitor Market, 2018-2025:  ($ millions)
• Principal Products
• Kyprolis (carfilzomib)
• Ninlaro (ixazomib)
• Velcade (bortezomib)
  • Table 7-1: Proteasome Inhibitors in Cancer Therapy
• Regional Market Summary
  • Figure: 7-2: Cancer Proteasome Inhibitor Market Summary by Geographic Region, Estimated 2018 and 2025  ($ millions) (United States, EMEA, Asia Pacific, Latin America)
• Competitor Summary
• Takeda
• Johnson & Johnson
• Amgen
  • Table 7-2: Cancer Proteasome Inhibitor Competitor Market Share, 2018 ($ millions)

Chapter 8: Targeted Cancer Therapies: Other Targeted Therapies

• Other Targeted Therapies Overview
• Market Outlook
  • Figure 8-1: Other Targeted Therapies Market, 2018-2025:  ($ millions)
• Principal Products
• mTOR Inhibitor ¾ Afinitor (everolimus)
• mTOR Inhibitor ¾ Torisel (temsirolimus)
• PI3K Inhibitor ¾ Zydelig
• PARP Inhibitor ¾ Lynparza
• PARP Inhibitor ¾ Zejula
• Apoptosis Inducer ¾ Venclexta
  • Table 8-1: Other Targeted Cancer Therapies
• Regional Market Summary
  • Figure: 8-2: Other Targeted Therapies Market Summary by Geographic Region, Estimated 2018 and 2025  ($ millions) (United States, EMEA, Asia Pacific, Latin America)

Chapter 9: Market Summary

• Market Influences
• Global Demographics
  • Table 9-1: Global Population, 1980 through 2050 (population in millions)
  • Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
• Cancer: A Growing Economic Burden
• Cost Containment
  • Table 9-2: The Cost of Monoclonal Antibodies
• Reimbursement Landscape: A Deciding Factor for Success
• The Biosimilar Movement
• Regional Market Overview
  • Table 9-3: Targeted Cancer Therapeutics Market Summary by Geographical Region, 2018-2025 ($ millions) (United States and Canada; Europe, Middle East, Africa (EMEA); Asia Pacific; Latin America; Global Market)
• United States and Canada
  • Table 9-4: Targeted Cancer Therapeutics Market Summary for U.S. and Canada, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Figure 9-2: Targeted Cancer Therapeutics for U.S. and Canada, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
• EMEA
  • Table 9-5: Targeted Cancer Therapeutics Market Summary for EMEA, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Figure 9-3: Targeted Cancer Therapeutics for EMEA, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
• Asia Pacific
  • Table 9-6: Targeted Cancer Therapeutics Market Summary for Asia Pacific, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Figure 9-4: Targeted Cancer Therapeutics for Asia Pacific, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
• Latin America
  • Table 9-7: Targeted Cancer Therapeutics Market Summary for Latin America, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Figure 9-5: Targeted Cancer Therapeutics for Latin America, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %

Chapter 10: Market Participants

• Top 15 Overview
  • Table 10-1: Global Market Participants for Targeted Cancer Therapeutics, Top 15 Companies, 2018  ($ in millions)
  • Figure 10-1: Global Market Share for Targeted Cancer Therapeutics, 2018 %
  • Figure 10-2: Growth in Targeted Cancer Therapeutics by Company 2010 vs. 2018 ($ in millions)
  • Figure 10-3: Growth Trend by Company, 2010-2018 CAGR: Targeted Cancer Therapeutics
• AbbVie, Inc.
  • Table 10-2: AbbVie Corporate Summary
• Adaptimmune Therapeutics plc.
  • Table 10-3: Adaptimmune Corporate Summary
• Advantagene, Inc.
  • Table 10-4: Advantagene Corporate Summary
• Agenus, Inc.
  • Table 10-5: Agenus Corporate Summary
• Amgen
  • Table 10-6: Amgen Corporate Summary
• Anchiano Therapeutics
  • Table 10-7: Anchiano Therapeutics Corporate Summary
• Apceth Biopharma GmbH & Co. KG
  • Table 10-8: Apceth Corporate Summary
• Apollomics, Inc.
  • Table 10-9: Apollomics Corporate Summary
• Aptevo Therapeutics
  • Table 10-10: Aptevo Corporate Summary
• AstraZeneca PLC
  • Table 10-11: AstraZeneca Corporate Summary
• Aurobindo Pharma Ltd.
  • Table 10-12: Aurobindo Corporate Summary
• Bayer AG
  • Table 10-13: Bayer Corporate Summary
• Bellicum Pharmaceuticals, Inc.
  • Table 10-14: Bellicum Pharmaceuticals Corporate Summary
• Biocon Ltd
  • Table 10-15: Biocon Corporate Summary
• BioInvent International AB
  • Table 10-16: BioInvent Corporate Summary
• bluebird bio, Inc.
  • Table 10-17: bluebird bio Corporate Summary
• Boehringer Ingelheim
  • Table 10-18: Boehringer Ingelheim Corporate Summary
• Bristol-Myers Squibb Company
  • Table 10-19: Bristol-Myers Squibb Corporate Summary
• Celgene Corporation
  • Table 10-20: Celgene Corporate Summary
• Celldex Therapeutics
  • Table 10-21: Celldex Therapeutics Corporate Summary
• Celltrion, Inc.
  • Table 10-22: Celltrion Corporate Summary
• Celsion Corporation
  • Table 10-23: Celsion Corporate Summary
• Clovis Oncology, Inc.
  • Table 10-24: Clovis Oncology Corporate Summary
• Cold Genesys, Inc.
  • Table 10-25: Cold Genesys Corporate Summary
• Dendreon Pharmaceuticals LLC
  • Table 10-26: Dendreon Corporate Summary
• Eisai Co., Ltd.
  • Table 10-27: Eisai Corporate Summar
• Eli Lilly & Company
  • Table 10-28: Eli Lilly Corporate Summary
• EMD Serono, Inc. (Merck KgaA)
  • Table 10-29: EMD Serono Corporate Summary
• Exelixis, Inc
  • Table 10-30: Exelixis Corporate Summar
• Gamida Cell Ltd
  • Table 10-31: Gamida Cell Corporate Summar
• Genprex, Inc
  • Table 10-32: Genprex Corporate Summar
• Gilead Sciences, Inc.
  • Table 10-33: Gilead Sciences Corporate Summary
• Immunomedics, Inc.
  • Table 10-34:  Immunomedics Corporate Summary
• Incyte Corporation
  • Table 10-35: Incyte Corporate Summary
• Innate Pharma S.A.
  • Table 10-36: Innate Pharma Corporate Summary
• Inovio Pharmaceuticals, Inc.
  • Table 10-37: Inovio Pharmaceuticals Corporate Summary
• Johnson & Johnson
  • Table 10-38: Johnson & Johnson Corporate Summary
• MacroGenics, Inc.
  • Table 10-39: MacroGenics Corporate Summary
• Merck & Co., Inc.
  • Table 10-40: Merck & Co. Corporate Summary
• Merrimack Pharmaceuticals, Inc.
  • Table 10-41: Merrimack Corporate Summary
• Nascent Biotech
  • Table 10-42: Nascent Biotech Corporate Summary
• Northwest Biotherapeutics, Inc.
  • Table 10-43: Northwest Biotherapeutics Corporate Summary
• Novartis AG
  • Table 10-44: Novartis Corporate Summary
• Oncolytics Biotech, Inc.
  • Table 10-45: Oncolytics Biotech Corporate Summary
• OncoMed Pharmaceuticals, Inc.
  • Table 10-46: OncoMed Pharmaceuticals Corporate Summary
• OncoSec Medical, Inc.
  • Table 10-47: OncoSec Medical Corporate Summary
• Oncternal Therapeutics
  • Table 10-48: Oncternal Therapeutics Corporate Summary
• Otsuka Holdings Co., Ltd.
  • Table 10-49: Otsuka Corporate Summary
• Pfizer, Inc.
  • Table 10-50: Pfizer Corporate Summary
• Puma Biotechnology, Inc.
  • Table 10-51: Puma Biotechnology Corporate Summary
• Regeneron Pharmaceuticals
  • Table 10-52: Regeneron Corporate Summary
• Roche (F. Hoffman-La Roche, Ltd.)
  • Table 10-53: Roche Corporate Summary
• Sanofi
  • Table 10-54: Sanofi Corporate Summary
• Seattle Genetics, Inc.
  • Table 10-55: Seattle Genetics Corporate Summary
• Sesen Bio
  • Table 10-56: Sesen Bio Corporate Summary
• Sorrento Therapeutics
  • Table 10-57: Sorrento Therapeutics Corporate Summary
• Takeda Oncology – Millennium Pharmaceuticals
  • Table 10-58: Takeda Oncology Corporate Summary
• TESARO, Inc.
  • Table 10-59: TESARO Corporate Summary
• TG Therapeutics, Inc.
  • Table 10-60: TG Therapeutics Corporate Summary
• Tocagen, Inc.
  • Table 10-61: Tocagen Corporate Summary
• Vascular Biogenics Ltd.
  • Table 10-62: Vascular Biogenics Corporate Summary
• ZIOPHARM Oncology, Inc.
  • Table 10-63: ZIOPHARM Oncology Corporate Summary